Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies !?
Braun
J
J
Rheumatology Klinikum B Franklin Free University Berlin, Germany. jbraun@zedat.fu-berlin.de
Sieper
J
J
D000208:Acute Disease; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D006801:Humans; D000069285:Infliximab; D018579:Patient Selection; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab